<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> is a new type of intracellular calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi>, different from the calcium entry blockers that are commonly employed for clinical use </plain></SENT>
<SENT sid="1" pm="."><plain>Since September 1995, the combination of fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> and ozagrel <z:chebi fb="199" ids="26708">sodium</z:chebi>, an inhibitor of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> synthesis, has been used to treat 60 patients at risk of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The effectiveness of this combination therapy was investigated by comparison with the outcome of 57 patients previously treated with only ozagrel <z:chebi fb="199" ids="26708">sodium</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The combination therapy was significantly more effective (p &lt; 0.01) in reducing the incidence of low density areas on computed tomography scans, and reduced, but not significantly, the occurrence of symptomatic vasospasm </plain></SENT>
<SENT sid="4" pm="."><plain>The combination therapy of fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> and ozagrel <z:chebi fb="199" ids="26708">sodium</z:chebi> has superior effectiveness over only ozagrel <z:chebi fb="199" ids="26708">sodium</z:chebi> in treating patients at risk of vasospasm after aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
</text></document>